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Abstract
Background: Endometriosis is a common disease characterized by the presence of a functional endometrium outside
the uterine cavity, causing pelvic pain, dysmenorrheal, and infertility. This disease has been associated to development
of different types of malignancies; therefore new blood vessels are essential for the survival of the endometrial implant.
Our previous observations on humans showed that angiogenesis is predominantly found in rectosigmoid
endometriosis, a deeply infiltrating disease. In this study, we have established the experimental model of rat peritoneal
endometriosis to evaluate the process of angiogenesis and to compare with eutopic endometrium.
Methods: We have investigated the morphological characteristics of these lesions and the vascular density, VEGF
and its receptor Flk-1 and MMP-9 expression, and activated macrophage distribution, using immunohistochemistry
and RT-PCR.
Results: As expected, the auto-transplantation of endometrium pieces into the peritoneal cavity is a well-established
method for endometriosis induction in rats. The lesions were cystic and vascularized, and demonstrated histological
hallmarks of human pathology, such as endometrial glands and stroma. The vascular density and the presence of VEGF
and Flk-1 and MMP-9 were significantly higher in endometriotic lesions than in eutopic endometrium, and confirmed
the angiogenic potential of these lesions. We also observed an increase in the number of activated macrophages (ED-1
positive cells) in the endometriotic lesions, showing a positive correlation with VEGF.
Conclusion: The present endometriosis model would be useful for investigation of the mechanisms of
angiogenesis process involved in the peritoneal attachment of endometrial cells, as well as of the effects of
therapeutic drugs, particularly with antiangiogenic activity.
Background
Endometriosis is a pathology defined as the presence of
endometrium-like tissue outside the uterine cavity,
which consists of proliferating functional endometrial
glands and stroma [1]. It is one of the most frequent
gynecological diseases, and is thought to occur in 7-10%
of women [2] but may even affect up to 60% of women
of reproductive age with pelvic symptoms or disturbance
of fertility [3]. The development and maintenance of the
disease is dependent on the recruitment of blood vessels
to the endometriotic lesions from pre-existing ones to
guarantee oxygen and essential nutrient supply [4]. It
has been shown that neovascularization is necessary for
the survival of tumor implants larger than 2-3 mm
3 [5],
and that endometriotic lesions recruit blood vessels by
inducing angiogenesis [6]. In addition, epidemiological
studies have shown that women with endometriosis
have an increased risk of different types of malignancies,
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[7,8].
The development of new blood vessels is a complex
dynamic process, which is characterized by a coordi-
nated sequence of humoral and cellular interactions [9].
Upon stimulation by angiogenic growth factors, the wall
of mature blood vessels becomes destabilized due to the
detachment of mural cells and the degradation of the
extracellular matrix that is a primordial step for the for-
mation of new vessels. Chen et al. (2004) [10] reported
higher metalloproteinase-9 (MMP-9) and lower tissue
inhibitor of MMPs-1 (TIMP-1) immunostaining in ecto-
pic and eutopic endometrium. This enables the endothe-
lial cells to migrate into the surrounding interstitium,
resulting in the formation of capillary buds and sprouts
[10]. Endothelial cells behind the migrating endothelium
of the sprouts proliferate so that the length and the dia-
meter of the newly developing blood vessels increase
continuously. Finally, the new vessel wall is stabilized by
the attachment of mural cells, including pericytes and
smooth muscle cells and the production of extracellular
matrix compounds [11].
Angiogenesis is considered as a major process in the
pathogenesis of endometriosis. Many factors are
involved in this complex mechanism, and the vascular
endothelial growth factor (VEGF) is an important med-
iator of angiogenesis; it is a potent endothelial cell mito-
gen, morphogen, and vascular permeability-inducing
agent [12,13]. VEGF binds to either of two tyrosine
kinase receptors, the fm5-like tyrosine kinase (flt) and
the kinase domain receptor (KDR or Flk-1) [14]. Perito-
neal endometriotic lesions with high proliferative activity
are also accompanied by high angiogenic activity, as
reflected by higher expression of VEGF-A in stroma and
glandular epithelium and VEGFR-2 in blood vessels
[15]. In our recent study, we showed that the vascular
density and the expression of VEGF and its receptor
VEGFR-2 (Flk-1) are significantly higher in deeply infil-
trating endometriosis affecting the ovary, bladder and
mainly the rectosigmoid, compared with the eutopic
endometrium [16].
Controlled clinical analyses of angiogenesis in human
endometriotic lesions are limited, because it is not pos-
sible to monitor the lesions without repeated laparosco-
pies. Thus, research into the fundamental mechanisms
by which menstrual endometrium adheres, invades and
establishes a functional vasculature to persist in an ecto-
pic site, as well as the development of new therapeutical
approaches, is best performed in experimental animal
models. In contrast to humans and non-human pri-
mates, estrous animals do not shed their endometrial
tissue and therefore do not develop endometriosis spon-
taneously. However, endometriosis can be induced by
transplanting endometrial tissue to ectopic sites, and the
establishment of an experimental model of endometrio-
sis may be a good way to study the endometriosis angio-
genesis process, and allow evaluation of the balance of
the many factors involved [17].
In this study, we established a rat experimental model
of peritoneal endometriosis, and we analyzed the vascular
density and expression of VEGF and its receptor VEGFR-
2 (Flk-1) and MMP-9, with the objective to evaluate the
angiogenesis process and its implication in the establish-
ment and growing of endometriosis. Our results indi-
cated an increase of angiogenesis in endometriotic tissues
similar to that observed in the human disease.
Methods
Animals
Animals were treated in accordance with protocols
approved by the Institutional Animal Care and Use
Internal Review Board of the Federal University of Rio
de Janeiro (IBCCF-009/2008). Female Sprague-Dawley
rats (200-250 g) with free access to water and food were
included in this study, after reaching maturity at 8
weeks of age.
Surgical Induction of Endometriosis
Twenty female rats were used in the experimental
induction of endometriosis, using the method described
by Vernon and Wilson (1985) [18]. Animals were
anesthetized with intramuscular injection of ketamine
and xylazine. The abdomen was opened through a 3-cm
midline incision to expose the uterus. One uterine horn
was ligated at both the uterotubal junction and the cer-
vical end, and was removed. The segment was placed in
phosphate-buffered saline at 37°C and split longitudin-
ally, and 5 × 5-mm pieces were sectioned. These
explants were then anchored onto the peritoneum on
the right side of the ventral abdominal wall by nonad-
sorbable polypropylene sutures (Prolene 6-0; Ethicon,
Piscataway, NJ). The abdomen was closed and the ani-
mals were allowed to recover from anesthesia.
The animals were divided into two groups to study
the implantation and the angiogenic potential of these
lesions. Group 1: 10 animals, analyzed 15 days after the
surgery; and Group 2: 10 animals, analyzed 30 days after
the surgery. After that, the animals were euthanized to
determine the attachment and viability of endometrial
explants. Also, from each experimental group, tissue
samples of eutopic endometrium were obtained for
establishing the control group. The surface area of the
explants was measured (length × width) to the nearest
0,1 millimeter using calipers. After dissection, each sam-
ple was immediately divided into two pieces. One piece
was fixed in 10% buffered formalin and embedded in
paraffin for histological and immunohistochemical stu-
dies. The other piece was frozen in liquid nitrogen for
RNA extraction.
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Formalin-fixed tissues were paraffin-embedded and cut
into 4-μm-thick sections. Part of the sections were
stained with Harris’ hematoxylin and eosin, and exam-
ined microscopically for the presence of histological
hallmarks of endometriosis, such as endometrial glands
and stroma.
The other paraffin-embedded tissue sections were
placed on silane-treated slides, and maintained at room
temperature. After dewaxing, the sections were treated
with a solution of 3% H2O2 in 0.01 mol/L phosphate-
buffer saline (PBS), pH 7.5, to inhibit endogenous perox-
idase activity. The slides were then immersed in 10
nmol/L citrate buffer (pH 6.0) and heated in a micro-
wave oven for 5 minutes to retrieve masked antigens; to
reduce nonspecific antibody binding; the sections were
then incubated with PBS containing a 10% solution of
normal goat serum and 5% bovine serum albumin for
30 minutes. Sections were incubated with the following
antibodies: polyclonal antibody against von Willebrand-
factor (vWF) A-082 (DakoCytomation, Carpinteria, CA)
at 1:200 dilution, monoclonal antibody against a-smooth
muscle actin (a-SMA) M0851 (DakoCytomation, Car-
pinteria, CA) at 1:100 dilution, monoclonal antibody
against VEGF SC-7269 (Santa Cruz Biotechnology,
Santa Cruz, CA) at 1:100 dilution, polyclonal antibody
against VEGFR-2 (Flk-1) SC-6251 (Santa Cruz Biotech-
nology, Santa Cruz, CA) at 1:200 dilution, and monoclo-
nal antibody against ED-1 macrophage antigen AB31630
(Abcam, Cambridge, MA) at 1:200 dilution. Incubations
were carried out overnight and then revealed using
LSAB2 Kit, HRP, rat (Dako-Cytomation, Carpinteria,
CA) with diaminobenzidine (3,3’-diaminobenzidine
tablets; Sigma, St. Louis, MO) as the chromogen and
counterstained with hematoxylin. For each case, negative
control slides consisted of sections incubated with anti-
body vehicle or no immune rabbit or mouse serum.
Histomorphometry
All tissues were examined by two blinded observers
using a 40× objective lens of a light microscope (Nikon,
Tokyo, Japan) connected to a digital camera (Coolpix
990; Nikon). Ten fields of an immunostained section
(von Willebrand-factor, a-SMA, VEGF, Flk-1 and ED-1)
were chosen at random and captured from each speci-
men. Quantification was assessed on captured high-
quality images (2048 × 1536 pixels buffer) using the
Image Pro Plus 4.5.1 (Media Cybernetics, Silver Spring,
MD). Data were stored in Adobe Photoshop, version
3.0, to enable uneven illumination and background color
to be corrected. The number of cross sections of vWF
and a-SMA-stained vessels and ED-1-stained macro-
phages was counted, and these numbers per square
millimeter of the lesion were calculated, as described by
Nap et al. (2004) [19].
A semiquantitative evaluation of immunohistochemical
staining for VEGF and Flk-1 was performed according to
the method described by Donnez et al. (1998) [20]. This
method involves the analysis of the distribution and the
intensity of staining within the endothelium and glandu-
lar epithelium or stroma. The histologic scores (H)f o r
VEGF and Flk-1 were calculated using the formula H =
ΣPi,w h e r ei is the intensity ranging from 0 (negative
cells) to 3 (deeply staining cells) and P is the percentage
of staining cells for each given i, with P values of 1, 2, 3,
4, and 5 indicating <15%, 15-50%, 50-85%, >85%, and
100% positive-staining cells, respectively. The staining
result was expressed as mean ± standard deviations.
Statistical Analyses
All statistical calculations were carried out using the
Stat-Xact-5 software program (CYTEL Software Cor-
poration, Cambridge, MA). The differences between
groups were calculated using nonparametric analyses
(Mann-Whitney U test). A P value of < 0.05 was estab-
lished as statistically significant.
Reverse transcription-polymerase chain reaction (RT-PCR)
To investigate the expression of VEGF and Flk-1 and
MMP-9 in eutopic endometrium and in endometriotic
lesions, RT-PCR was performed. Total RNA was
extracted from the tissues in TRIzol reagent (Invitrogen,
Carlsbad, CA, USA) according to the manufacturer’s
protocol. The purity and integrity of the RNA were
checked by gel electrophoresis. One microgram of total
RNA was subjected to reverse transcription with a com-
mercially available kit (the cDNA First Chain Amplifica-
tion System, GIBCO-BRL) according to the
manufacturer’s protocol. Amplification for VEGF cDNA
was started with a 4-minute denaturation at 95°C fol-
lowed by cycles of 30 seconds of denaturation at 94°C,
45 seconds of annealing at 61°C, and 45 seconds of
extension at 72°C. The PCR profile for Flk-1 began with
the 4-minute initial denaturation at 95°C, followed by
cycles of 30 seconds of denaturation at 94°C, 45 seconds
of annealing at 58°C, and 45 seconds of extension at 72°
C. Amplification for MMP-9 cDNA was performed
according to the following profile: initial denaturations
at 94°C for 5 min, then 30 cycles at 94°C for 1 min 30 s,
63°C for 2 min and 72°C for 1 min. Transcripts were
quantified after normalization with the endogenous con-
trol (GAPDH). Amplification for GAPDH cDNA was
started with a 4-minute denaturation at 94°C followed
by cycles of 30 seconds of denaturation at 95°C, 45 sec-
onds of annealing at 63°C, and 45 seconds of extension
at 72°C. The primers used for VEGF, Flk-1, MMP-9,
and GAPDH amplification were: [1] VEGF: sense: 5’-
ACC ATG AAC TTT CTG CTC-3’,a n t i s e n s e :5 ’-GGA
CGG CTT GAA GAT ATA-3’; [2] Flk-1: sense: 5’-GCA
CTG AAT TAT GGG AGA-3’,a n t i s e n s e :5 ’-ATG TGA
TTT TCT TCT TGA TG-3’; [3] MMP-9: sense: 5’-GTT
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TGC TGG ATG TCT TTT ATG TCG-3’;[ 4 ]G A P D H :
sense: 5’-CAC CAC CAT GGA GAA GGC-3’, antisense:
5’-CCA TCC ACA GTC TTC TGA-3’. Final PCR pro-
ducts were subjected to electrophoresis through a 2%
agarose gel and stained with ethidium bromide. Semi-
quantitative RT-PCR was determined by agarose gel
electrophoresis, GelDoc 2000 digitization, Scion Image
Alpha 4.0.3.2. For each primer pair, assays were
designed to detect PCR product accumulation in the
middle of the linear range to facilitate their relative
quantification.
Results
Morphological characterization of rat peritoneal
endometriosis
Endometriosis was induced by transplanting endome-
trial tissue to the rat peritoneal wall. The endometrial
explants took well to the abdominal wall and produced
viable implants in 18 (90%) animals of 20. The mor-
phological characteristics of endometriotic lesions were
similar in both groups (15 and 30 days after the
implantation). Most of the explants were found to be
well vascularized and cystic, resembling human perito-
neal endometriosis (Fig. 1A, B). Compared between
groups, there was no detectable difference in size; how-
ever they were larger than the tissue fragment
implanted, as shown in the measurements of the
macroscopic area (Fig. 1F). The histological characteri-
zation of endometriotic lesions revealed the presence
of endometrial glands and stroma, very similar to that
observed in eutopic endometrium (Fig. 1C, D, E). We
have previously observed the endometriotic lesions 90
days after the implantation and we did not detect dif-
f e r e n c ei ns i z ec o m p a r e dw i t ht h el e s i o n so f3 0d a y s
(data not shown).
Figure 1 Morphological characteristics of rat peritoneal endometriotic lesions. Lesions after 15 days (A, C) and 30 days (B, D), eutopic
endometrium (E) and histogram of implant areas (F). Most of the explants were well vascularized (arrowheads) and cystic (arrows), resembling
human peritoneal endometriosis. Compared between groups, there was no detectable difference in the lesion size. Histologically, the
endometriotic tissues (C, D) were similar to the eutopic endometrium (E) because they both contained endometrial glands and stromal cells, as
revealed by hematoxylin and eosin coloration. Magnification × 200.
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Microvessel density was determined on the basis of vWF
and aSMA-positive vessel immunodistribution. These
markers were observed in the vessels located throughout
the stroma, mainly around the glands. Comparison
between the eutopic endometrium and the established
endometriotic lesions revealed that there were more
positive microvessels in the stroma around the glands in
samples of endometriosis (Fig. 2). These observations
were confirmed by the histomorphometry evaluation
(Table 1). Although there was no significant difference
between vWF in both endometriosis groups, the staining
for vWF at 15 days seemed to be more intense than
staining on day 30. In contrast, the immunodistribution
of aSMA-positive vessels were more numerous in endo-
metriosis samples after 30 days (Fig. 2 and Table 1).
Expression of mRNA encoding for VEGF, Flk-1 and MMP-9
The mRNA transcripts of VEGF, Flk-1 and MMP-9 were
analyzed in endometriotic lesions and in eutopic endo-
metrium by quantitative RT-PCR in order to evaluate the
expression of these genes. The levels of VEGF, Flk-1 and
MMP-9 mRNA transcripts in the endometriotic lesions
were higher than in the eutopic endometrium (Fig. 3).
VEGF, Flk-1, and ED-1 immunodistribution
The immunoreactivity of VEGF and Flk-1 was similar
and detected focally in the cytoplasm of endothelial
cells, glandular epithelial cells and diffusely in stromal
cells, in both eutopic and ectopic endometrial tissues
(Fig. 4). As expected, VEGF and Flk-1 immunoreactions
were more intense in endometriosis than in eutopic
endometrium. Comparing the endometriosis after 15
and 30 days, there were no differences in these angio-
genic markers, as shown in the histological scores
(Table 1).
The presence of macrophages in the tissues was ana-
lyzed using the macrophage activation marker ED-1.
This immunodistribution was observed in the cells in
the stroma, concentrated around the glands (Fig. 4). The
numbers of activated macrophages in samples of endo-
metriosis were higher than in eutopic endometrium. In
addition, the endometriotic lesions after 30 days
contained more of these cells compared to those after
15 days, as shown in Table 1.
Discussion
The pathogenesis of endometriosis remains unclear, but
it is generally considered that the development of pelvic
endometriosis may be a consequence of implantation of
viable endometrial tissue in ectopic sites via retrograde
menstruation [21]. However, this theory fails to explain
the presence of endometriosis in such remote areas as
the lungs, skin, and lymph nodes. The coelomic meta-
plasia theory claims that formation of endometriomas in
the ovary or rectovaginal endometriosis is caused by
metaplasia of the coelomic epithelium, perhaps induced
by environmental factors [22,23]. In addition to the ret-
rograde flow of exfoliated endometrium, new blood ves-
sels are essential for the survival of the implant, and
therefore for the development of endometriosis. This
study showed that, in a rat peritoneal endometriosis
model, the angiogenic markers were related to the
establishment of the lesions, confirming that this model
is suitable to investigate the angiogenesis process.
The autotransplantation of uterine pieces into the
peritoneal cavity is a well-established method for induc-
tion of endometriosis in rats [18,24]. In the present
study, this model of autologous endometrial explants
was established at 15 days in 18 (90%) animals of 20,
and the explants developed into large, ovoid, fluid-filled,
well vascularized, cystic structures composed of endo-
metrial elements. Any difference was observed in the
macroscopic aspect of these cystic structures on 30
days, and also after that (90 days, data not shown). In
addition, we have shown that these ectopic endome-
trium fragments also showed histological characteristics
of the human disease, including highly vascularized
lesions containing endometrial glands and stroma.
These results were in agreement with those of Dogan et
al. (2004) [25], who reported that the endometrial
explants produced viable implants in 26 of 30 animals
(86.6%), and that most of the explants were well
vascularized.
Table 1 Histological scores of Von Willebrand Factor (vWF), alpha-Smooth Muscle Actin (a-SMA), Vascular Endothelial
Growth Factor (VEGF), Kinase Domain Receptor (Flk-1) and ED-1-macrophage in eutopic endometrium and
endometriotic lesions after15 and 30 days.
Cases vWF (number of
vessels/mm
2)
a-SMA
(number of vessels/
mm
2)
VEGF
(% of positive
staining cells)
Flk-1
(% of positive
staining cells)
ED-1
(number of
macrophage/mm
2)
Eutopic endometrium 8.1 ± 0.73 5.1 ± 0.73 5.68 ± 0.10 6.46 ± 0.12 7.6 ± 1.07
Endometriosis 15 days 21.5 ± 1.35
a 11.3 ± 1.15
a 8.52 ± 0.19
a 9.81 ± 0.11
a 34.2 ± 0.78
a
Endometriosis 30 days 20.6 ± 0.84
a 19.2 ± 1.03
ab 8.43 ± 0.12
a 10.31 ± 0.18
a 40.2 ± 1.03
a
a P < 0.05 (the scores for all markers are significantly higher in endometriotic lesions compared to eutopic endometrium).
b P < 0.05 (the scores are significantly higher in endometriotic lesions after 30 days for a-SMA compared to lesions with 15 days).
Values are mean ± standard error.
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strated that angiogenesis is higher in endometriotic
lesions compared with the eutopic endometrium. Micro-
vessel density was determined on the basis of vWF and
a-SMA-positive vessels. The distribution of these vessel
markers was more positive in stroma around the glands
in samples of endometriosis. Although no significant dif-
ference was observed between the vWF positive vessels
in the two groups, the immunoreaction seemed to be
more intense on day 15. It could be related to the micro-
vessel size and that the endothelial cell might not be adja-
cent to other pericyte or vice versa. By other hand, the a-
SMA-positive vessels were more numerous in samples of
endometriosis at day 30 than at day 15. This difference is
related to the fact that the most of the blood vessels are
mature, as illustrated by their association with aSMA-
positive pericytes [4]. These observations indicated that
the development of new vessels is necessary for the estab-
lishment and the maintenance of the endometriotic
lesions, and also that the neovessels formed were more
mature in endometriosis after 30 days. Using the same
markers in the nude-mouse model of endometriosis, Nap
et al. (2004) [19] demonstrated that the development of
new blood vessels remains of pivotal importance for the
maintenance and growth of endometriosis.
One of the main characteristics of endometriosis is its
inflammatory nature. It has been shown that cytokines
released from immune cells play an important role in
Figure 2 Microvessel density was determined on the basis of vWF and aSMA-positive vessels. The distribution of these markers was
observed in the vessels located throughout the stroma, mainly around the glands. Comparing eutopic endometrium and the established
endometriotic lesions, there were more positive microvessels (arrows) in the stroma around the glands in endometriosis samples after 15 and 30
days. In contrast, aSMA-positive vessels were more abundant in the lesions after 30 days. Magnification × 400.
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cytokines possess angiogenic activity [26,27]. VEGF is
the most-prominent and most-studied proangiogenic
factor in endometriosis, and it is widely believed that
VEGF is the main stimulus for angiogenesis and
increased vessel permeability in this disease [6]. Its
activity depends on its binding to different receptors,
such as VEGFR-2 (Flk-1). In our model, we were able to
demonstrate that the expression of VEGF and Flk-1 is
enhanced in endometriotic lesions as compared with
controls. Their immunodistributions were observed
focally in the cytoplasm of endothelial and glandular
epithelial cells and diffusely in stromal cells, and were
more intense in ectopic endometrial tissues. It was also
observed that the number of activated macrophages
(ED-1 positive cells) increased in endometriotic lesions.
These results are in agreement with other studies that
have shown that VEGF is strongly expressed by endo-
metriotic lesions and activated macrophages [12,28]. Sig-
nificantly increased VEGF levels have been found in the
peritoneal fluid and lesions of endometriosis patients
compared to controls or eutopic endometrium, respec-
tively [20]. These authors discovered that red, highly
active endometriotic lesions contain the highest VEGF
concentrations. In addition, Wang et al. (2005) [29]
reported a higher Flk-1 expression in endometriosis
Figure 3 Expression of mRNA encoding for VEGF, Flk-1 and
MMP-9 in eutopic endometrium and endometriotic lesions as
assayed by RT-PCR (A) and densitometry of bands (B). Lane 1,
negative control (no cDNA); Lane 2, eutopic endometrium; Lane 3,
lesions after 15 days; Lane 4, lesions after 30 days. The levels of
VEGF, Flk-1 and MMP-9 mRNA transcripts in the endometriotic
lesions were higher than in eutopic endometrium. Glyceraldehyde-
3-phosphate dehydrogenase (GAPDH) mRNA was studied as
constitutive housekeeping genes.
Figure 4 Angiogenesis pattern of eutopic endometrium (A, D, G), and endometriotic lesions after 15 days (B, E, H) and 30 days
(C, F, I). The immunoreactivity of VEGF and Flk-1 were detected mainly in the cytoplasm of endothelial (arrows) and glandular epithelial cells
(arrowheads) but also in stromal cells (asterisks) in both eutopic and ectopic endometrial tissues. As expected, VEGF and Flk-1 immunoreactions
were more abundant in endometriosis than in the eutopic endometrium. The distribution of the ED-1-positive macrophages was observed in
the cells in the stroma, concentrated around the glands. There were more activated macrophages in samples of endometriosis than in eutopic
endometrium (black squares). Magnification × 400.
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have been associated with neovascularization.
Peritoneal macrophages and activated lymphocytes
seem to play an integral role in the secretion of proin-
flammatory/proangiogenic cytokines. For example, in
patients with endometriosis, interleukin-1b (IL-1b)i s
produced by activated macrophages and results in the
increased expression of VEGF [24]. In a mouse model of
endometriosis, it was reported that interleukin-6 (IL-6)
together with tumor necrosis factor alpha (TNF-a)w a s
secreted by macrophages, and resulted in upregulation of
VEGF from infiltrating neutrophils and macrophages
[30]. These data and our results support the idea that the
microenvironment of endometriosis is a locale of impor-
tant secretion of angiogenic factors that play a key role in
the establishment and maintenance of endometriotic
lesions, and suggest that the balance of these local pro-
antiangiogenic factors and cytokines may determine
whether endometriotic lesions develop and grow. In this
context, the behavior of endometriosis tissue is very simi-
lar to that observed in tumor growth [31].
Several studies have indicated endometriosis as a risk
factor and various histological and molecular genetic stu-
dies have even indicated that endometriosis may trans-
form into cancer or that it could be considered a
precursor of cancer [32-34]. Goumenou et al. [35], by
microsatellite analysis, demonstrated that loss of hetero-
zygosity on p16(Ink4), GALT, and p53, as well as on
APOA2, a region frequently lost in ovarian cancer,
occurs in endometriosis, even in stage II of the disease.
The occurrence of such genomic alterations may repre-
sent, therefore, important events in the development of
endometriosis. However, despite the histological and epi-
demiological evidence linking endometriosis and ovarian
cancer, it is still not clear if endometriosis is a real pre-
cursor of ovarian cancer, or whether there is an indirect
link involving common environmental, immunological,
hormonal or genetic factors [35]. It has been clearly
demonstrated that activation of a mutated K-ras gene is a
fundamental step in the genesis and progression of ovar-
ian cancer [36]. Further genetic studies are required for
delineation of the risk of several malignancies and in par-
ticular of ovarian cancer in women with endometriosis.
The invasive properties of endometrium are also
related to the increase of its proteolytic activity, resulting
in the development of endometriosis. Chung et al. (2001)
[37] showed that ectopic endometrium expressed signifi-
cantly higher levels of MMP-9 mRNA and lower levels of
TIMP-3 mRNA, compared to eutopic endometrium from
normal and endometriosis patients. By immunohisto-
chemistry, greater expression of MMP-9 and less expres-
sion of TIMP-1 in ectopic endometrium than in eutopic
endometrium was also observed [10]. Recently, it was
demonstrated in mice that the treatment of 15-Epi-
lipoxin A4 (LXA4) may inhibit the progression of endo-
metriosis possibly by lowering the concentrations and the
activities of MMP-2 and MMP-9 [38]. In our model,
MMP-9 mRNA expression, as expected, was greater in
endometriotic lesions than in eutopic endometrium. Our
results indicate a direct role for MMPs in the ability of
rat endometrium to establish ectopic lesions within the
peritoneum. By other hand, it is known that proteogly-
cans play an important role in the maintenance of vascu-
lar integrity. Kirn-Safran et al. (2008) [39] showed that
proteoglycans are involved in angiogenesis by presenting
and modulating a wide range of growth factors such as
fibroblast growth factor-2 and -10 and VEGF on their
glycosaminoglycan (GAG) side-chains. Recently, we have
demonstrated that chondroitin sulfate (CS) GAG was the
dominant sulfated GAG present in stroma of deeply infil-
trating endometriosis lesion foci [40], as also observed in
eutopic endometrium [41]. Taken together, these studies
suggest that the high concentration of CS in endometrio-
sis could be related to the angiogenesis process, and rein-
force the importance of extracellular matrix
metalloproteinases in the progression of endometriosis.
Animal models of endometriosis are of extreme value
and indispensable for the evaluation of pathophysiological
mechanisms underlying the development of this prevalent
gynaecological disease. Other possible and important use
for this method is to test the angiogenic therapy for endo-
metriosis. Although there are disadvantages in extrapolat-
ing data across species, it is still possible to utilize animal
models to study events involved in the pathogenesis of
endometriosis that are not accessible in humans. Rat endo-
metriotic tissues and cells perform similarly to human
endometriotic cells, as revealed in this study. While the rat
model for endometriosis has been used to identify effects
of ectopic endometrial tissue adhesion and growth, the
mechanisms eliciting these effects remain elusive. In gen-
eral, animal models will help to develop novel non-invasive
diagnostic tools and improved therapeutical approaches
for improved treatment of endometriosis in women.
Conclusions
Here we originally showed that the pattern of angio-
genic process in rat endometriosis is very similar to
human disease. Despite recent advances in the field,
there is still only a limited amount of knowledge about
the mechanisms regulating the complex dynamic pro-
cess of blood-vessel development in endometriotic
lesions. The introduction of sophisticated in vivo models
of peritoneal and extra-peritoneal endometriosis, which
allow for detailed monitoring of angiogenesis within
endometriotic lesions under standardized conditions,
certainly will help to clarify these mechanisms. Finally, it
certainly would be important to better understand the
angiogenesis process in a tumor growth.
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